wellknown
immunosuppress
drug
cyclosporin
inhibit
replic
variou
virus
includ
coronavirus
bind
cellular
cyclophilin
thu
inactiv
cistran
peptidylprolyl
isomeras
function
viral
nucleocapsid
protein
inevit
genom
encapsid
replic
demonstr
interact
n
protein
cyclophilin
cyclophilin
b
cyclophilin
inhibitor
abolish
interact
upon
infect
cyclophilin
stay
evenli
distribut
throughout
cell
wherea
cyclophilin
b
concentr
erbleblik
structur
show
inhibitori
potenti
nonimmunosuppress
csa
deriv
alisporivir
compound
luciferas
replic
human
hepatoma
cell
h
time
point
post
infect
ec
low
micromolar
rang
thu
nonimmunosuppress
csa
deriv
effect
inhibit
replic
suggest
possibl
candid
treatment
hcov
infect
interrupt
interact
cypa
n
protein
csa
deriv
suggest
mechan
cypa
inhibitor
suppress
viral
replic
coronavirus
cov
infect
number
mammalian
speci
mostli
caus
respiratori
gastrointestin
tract
patholog
perlman
netland
six
human
cov
name
sar
sever
acut
respiratori
syndrom
cov
mer
middl
east
respiratori
syndrom
cov
zoonot
origin
corman
et
al
first
four
virus
mainli
target
respiratori
tract
associ
common
cold
wherea
sarsand
merscov
highli
pathogen
high
mortal
rate
cui
et
al
although
great
effort
made
discov
antim
agent
screen
defin
drug
librari
cao
et
al
de
wild
et
al
dyall
et
al
lafemina
effect
drug
treatment
avail
cov
order
identifi
hosttarget
agent
hta
recent
perform
virushost
proteinprotein
interact
screen
test
individu
sarscov
orf
human
cdna
librari
util
highthroughput
techniqu
pfefferl
et
al
studi
identifi
cyclophilin
fkbp
protein
cellular
interact
partner
viral
protein
cyclophilinbind
immunosuppress
drug
cyclosporin
csa
replic
inhibitor
variou
human
anim
cov
includ
sarscov
felin
cov
transmiss
gastroenter
viru
infecti
bronchiti
viru
respect
followup
studi
found
nonimmunosuppress
csa
deriv
alisporivir
alv
compound
inhibit
replic
cypa
essenti
cellular
molecul
requir
viru
replic
carbajolozoya
et
al
similar
inhibitori
properti
csa
deriv
cov
arteriviru
replic
belong
order
nidoviral
describ
de
wild
et
al
de
wild
et
al
de
wild
et
al
cyclophilin
ubiquit
enzym
catalyz
cistran
isomer
prolyl
peptid
bond
ppias
activ
thu
facilit
protein
fold
lang
et
al
promin
human
http
receiv
juli
receiv
revis
form
august
accept
octob
cyclophilin
cypa
import
role
mani
biolog
process
protein
fold
traffick
nigro
et
al
addit
coincident
bind
csacypa
complex
caus
immunosuppress
ie
prevent
activ
transcript
regul
nuclear
factor
activ
tcell
nfat
inhibit
ppias
activ
prevent
correct
fold
cellular
also
number
viral
protein
indispens
viral
replic
shown
first
human
immunodefici
viru
hepat
c
viru
hcv
hopkin
gallay
lin
gallay
thu
cyclophilin
discuss
therapeut
target
viral
liver
diseas
naoumov
treatment
viru
infect
rel
low
pathogen
inhibit
ppias
immunosuppress
activ
csa
desir
number
csa
deriv
develop
fulfil
criteria
alv
membreno
et
al
hopkin
et
al
sangliferin
sanglier
et
al
seri
new
compound
describ
recent
carbajolozoya
et
al
et
al
prell
et
al
alv
experienc
substanti
clinic
test
safeti
databas
develop
patient
treat
week
administ
small
number
patient
short
proofofconcept
trial
compound
sangliferin
given
patient
yet
demonstr
inhibitori
effect
nonimmunosuppress
csa
deriv
replic
variou
hepatoma
cell
line
requir
cypa
interact
viral
nucleocapsid
protein
viru
propag
cell
mous
antibodi
recogn
nprotein
obtain
ingenasa
spain
sastr
et
al
antilamin
antippia
antippib
purchas
biomol
abcam
thermofish
respect
secondari
antibodi
receiv
biomol
goat
antirabbitighors
radish
peroxidas
hrp
rabbitantigoatighrp
sigma
aldrich
antimouseighrp
alisporivir
formerli
provid
novarti
basel
switzerland
csa
rapamycin
rapa
obtain
sigmaaldrich
germani
cyclosporin
h
csh
synthes
accord
publish
procedur
whitak
casp
synthesi
compound
describ
recent
carbajolozoya
et
al
et
al
human
hepatocellular
carcinoma
cell
cell
blight
et
al
sub
clone
maintain
dulbecco
modifi
eagl
medium
invitrogen
karlsruh
germani
supplement
fetal
bovin
serum
mm
lglutamin
vv
nonessenti
amino
acid
uml
penicillin
streptomycin
feigelstock
et
al
lunet
koutsoudaki
et
al
cell
describ
cell
viabil
determin
luminesc
cell
viabil
assay
promega
virus
express
renilla
luciferas
luc
green
fluoresc
protein
gfp
carbajolozoya
et
al
cervantesbarragan
et
al
report
gene
use
examin
inhibitori
effect
compound
gener
cell
infect
moi
incub
two
day
presenc
increas
concentr
inhibitor
cultur
medium
viral
replic
determin
measur
renilla
luciferas
activ
gfp
fluoresc
evalu
replic
cell
line
cell
split
onto
steril
coverslip
grown
confluenc
infect
respect
moi
indic
time
point
noninfect
infect
cell
fix
formaldehyd
min
wash
twice
pb
subject
dapi
cell
signal
stain
two
wash
coverslip
airdri
mount
fluoresc
mount
medium
dako
inspect
use
leica
dmi
fluoresc
microscop
magnif
immunofluoresc
analysi
cell
seed
onto
steril
cover
slip
plate
costar
cell
densiti
cell
per
well
h
cell
infect
wt
moi
h
co
infect
cell
wash
pb
incub
csa
alv
inhibitor
ethanol
solvent
control
cultur
medium
immunostain
cell
fix
overnight
paraformaldehyd
subsequ
block
bsa
pb
gibcolif
technolog
overnight
fix
cell
incub
h
follow
primari
antibodi
dilut
pb
bsa
mous
antidsrna
clone
scicon
rabbit
anticypa
abcam
rabbit
anticypb
thermofish
mous
antipdi
thermofish
bd
bioscienc
mous
thermofish
mous
santacruz
mous
antipabp
sigma
aldrich
incub
cell
wash
three
time
pb
incub
h
dark
secondari
antibodi
goat
antirabbitfitc
sigma
aldrich
goat
thermofish
pb
contain
goat
serum
room
temperatur
cell
wash
pb
cell
nuclei
stain
dapi
sigma
aldrich
min
dark
three
wash
pb
coverslip
airdri
mount
fluoresc
mount
medium
dako
inspect
use
leica
dmi
fluoresc
microscop
magnif
nprotein
express
presenc
inhibitor
cypa
variant
analys
describ
recent
carbajolozoya
et
al
briefli
cell
infect
viru
moi
h
sixwel
plate
viru
wash
pb
inhibitor
ad
medium
respect
concentr
h
cell
harvest
lyse
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
dtt
proteas
inhibitor
cocktail
hoffmann
la
roch
protein
separ
sdspage
electroblot
onto
nitrocellulos
membran
latter
block
milk
powder
tbst
buffer
primari
antibodi
usual
incub
overnight
secondari
antibodi
incub
perform
room
temperatur
h
incub
step
membran
wash
three
time
tbst
min
hrp
develop
immobilon
western
blot
hrp
chemiluminisc
substrat
millipor
membran
expos
xray
film
agfa
construct
split
yfp
vector
describ
recent
malauer
et
al
briefli
pdestcmycyfp
n
cmycyfp
n
amino
acid
fuse
nterminu
test
gene
pdesthayfp
c
hayfp
c
amino
acid
fuse
nterminu
test
gene
pdestctcmycyfp
n
cmycyfp
n
fuse
cterminu
test
gene
pdestcthayfp
c
hayfp
c
fuse
cterminu
test
gene
serv
splityfp
vector
gene
encod
n
protein
cyclophilin
ppia
first
bp
vector
consequ
lrclone
pdestcmycyfp
n
pdesthayfp
c
pdestctcmycyfp
n
pdestcthayfp
c
vector
yield
construct
splityfp
assay
amplifi
primer
ctacagtcaaatgggc
aagaaagctgggtctcmgtttacttcatcaattatgtcag
hppia
amplifi
primer
ppiaattfor
ppiaattrev
agttgtccacagtcagcaatgg
bp
lr
reaction
perform
accord
manufactur
instruct
cell
seed
directli
onto
autoclav
coverslip
cultur
plate
plasmid
pdestcmycyfp
n
ppia
yfp
n
ppia
pdesthayfp
c
n
yfp
c
empti
split
yfp
vector
combin
thereof
cotransfect
cell
confluenc
use
lipofectamin
thermofish
h
transfect
cell
coverslip
examin
directli
microscop
leica
b
pictur
taken
object
human
hepatocellular
carcinoma
cell
support
replic
number
virus
includ
hcv
bartenschlag
pietschmann
sarscov
merscov
raj
et
al
number
mutant
cell
line
blight
et
al
feigelstock
et
al
frieb
et
al
gener
order
increas
hepat
c
viru
hcv
permiss
viral
replicon
propag
instanc
cell
carri
mutat
cytosol
retino
acidinduc
gene
rigi
pattern
recognit
receptor
trigger
type
interferon
pathway
sens
hcv
dsrna
carri
mutat
outsid
rigi
code
region
cell
support
high
level
hcv
rna
replic
order
test
permiss
differ
hepatoma
cell
line
replic
infect
cell
shown
suppl
fig
cell
line
permiss
infect
similar
extend
dapi
stain
cell
nuclei
indic
compar
confluenc
cell
replic
effici
cell
line
analys
detail
although
infect
slightli
less
effect
compar
chose
primarili
work
cell
line
cypa
knockdown
mutant
avail
von
hahn
et
al
recent
report
biochem
immunolog
characterist
inhibitori
effect
number
csaderiv
compound
replic
carbajolozoya
et
al
molecul
includ
csa
alv
well
newli
develop
csa
posit
compound
structur
shown
fig
test
inhibitori
effect
replic
use
recombin
virus
express
renilla
luciferas
gfp
fig
show
replic
cell
reflect
renilla
luciferas
activ
h
pi
correspond
ec
effect
inhibitori
concentr
valu
list
tabl
clearli
demonstr
similarli
csa
nonimmunosuppress
molecul
alv
fig
compound
fig
inhibit
replic
low
micromolar
rang
cell
viabil
slightli
affect
highest
caption
next
page
concentr
use
control
includ
csh
rapamycin
csh
stereoisom
csa
dmethylvalin
posit
substitut
natur
lmethylvalin
follow
minor
affin
cypa
substitut
abrog
immunosuppress
antiinflammatori
properti
csa
de
pauli
et
al
legru
et
al
fig
show
slight
residu
inhibitori
activ
csh
prepar
might
result
low
cypa
affin
trace
csalik
impur
present
csh
prepar
due
chemic
similar
stereoisom
molecul
impur
difficult
remov
product
batch
also
observ
low
inhibit
cypa
ppias
assay
compound
immunosuppress
drug
rapamycin
use
cyclophilinindepend
control
molecul
test
effect
immunosuppress
cov
replic
bind
oppos
interfer
mtor
mechanist
target
rapamycin
pathway
inhibit
serinethreonin
protein
kinas
huang
et
al
fig
show
background
inhibitori
activ
rapamycin
thu
lack
effect
inhibit
viral
replic
csh
affect
ppias
activ
cyclophilin
strongli
argu
requir
function
coronaviru
replic
n
protein
multifunct
protein
mcbride
et
al
requir
viru
replic
propag
replicon
chang
et
al
primari
function
encapsid
protect
genom
rna
lack
n
protein
thu
measur
lack
viral
replic
studi
effect
csa
alv
compound
viral
n
protein
express
cell
incub
concentr
respect
inhibitor
h
western
blot
analysi
cell
perform
util
antin
antibodi
fig
demonstr
decreas
n
protein
presenc
alv
compound
case
alv
n
protein
detect
anymor
similarli
presenc
posit
control
csa
also
decreas
n
protein
express
wherea
csh
rapamycin
allow
signific
n
protein
synthesi
even
clear
whether
inhibitor
act
cyclophilin
bind
n
protein
viral
protein
howev
viral
n
protein
essenti
replic
synthes
presenc
inhibitor
sarscov
n
protein
report
bind
cypa
vitro
luo
et
al
test
whether
n
protein
bind
directli
cypa
split
yfp
interact
experi
live
cell
experiment
proteinprotein
interact
system
describ
recent
malauer
et
al
base
split
yfp
n
yfp
n
c
yfp
c
termin
halv
fuse
dna
level
two
protein
test
interact
upon
interact
two
protein
two
yfp
fragment
assembl
function
yfp
demonstr
fluoresc
fig
left
panel
demonstr
direct
interact
cypa
protein
use
fusion
construct
yfp
n
ppia
yfp
c
n
control
combin
use
yfp
n
yfp
c
one
fusion
partner
neg
upon
addit
csa
alv
fluoresc
signal
disappear
almost
complet
indic
direct
interrupt
interact
cypa
n
protein
quit
interestingli
earlier
interact
studi
hint
interact
cypa
sarscov
xdomain
also
call
macrodomain
lei
et
al
pfefferl
et
al
right
panel
fig
also
found
interact
cypa
ppiayfp
n
xdomain
c
howev
csa
alv
block
interact
cypb
might
also
import
player
viru
replic
appli
left
yax
repres
percentag
reduct
viru
replic
rlu
rel
light
unit
renilla
luciferas
activ
black
line
linear
left
panel
log
scale
right
panel
indic
inhibitor
concentr
given
xaxi
cell
viabil
red
line
mocktreat
cell
set
shown
right
yax
left
panel
measur
taken
h
pi
csh
rapa
serv
control
graph
plot
use
prism
graphpad
softwar
inc
nonlinear
regress
variabl
slope
algorithm
curv
fit
respect
inhibitor
ec
calcul
tabl
ec
valu
individu
inhibitor
determin
h
pi
cytotox
inhibitor
compound
determin
compar
result
absorb
mean
absorb
control
well
solvent
use
luminesc
cell
viabil
assay
express
percentag
cell
viabil
cytotox
concentr
cc
defin
quantiti
inhibitor
gener
cell
viabil
compar
control
valu
percentag
cell
viabil
plot
inhibitor
concentr
graphpad
prism
version
cc
determin
use
nonlinear
regress
statist
inhibitor
vs
normal
respons
infect
cell
cell
treat
h
increas
concentr
alv
compound
rapa
csa
csh
process
wb
analysi
measur
viral
replic
nprotein
detect
mous
mab
n
rabbit
antilamin
antibodi
use
detect
lamin
load
control
analog
setup
use
cypa
test
possibl
interact
cypb
protein
shown
fig
lower
panel
could
demonstr
interact
irrespect
orient
split
yfp
fusion
protein
csa
alv
block
activ
cyclophilin
ab
far
inhibitori
effect
replic
exclus
attribut
one
cyclophilin
reason
possibl
coloc
cyclophilin
marker
viral
replic
site
replic
might
give
hint
relev
two
protein
therefor
visual
effect
inhibitor
intracellular
local
cypab
dsrna
immunofluoresc
assay
presenc
absenc
viru
express
level
cypa
similar
distribut
throughout
cytoplasm
nucleu
cell
irrespect
condit
fig
anticypa
column
contrast
cypb
locat
untreat
cell
inhibitor
viru
almost
exclus
cytoplasm
fig
etohmock
etoh
panel
earlier
work
known
csa
alter
cypb
traffick
secretori
pathway
price
et
al
found
cypb
inhibitor
treatment
caus
reloc
sequestr
foci
nucleu
strong
reduct
express
fig
right
panel
small
green
dot
csaalv
mockand
cell
interestingli
viru
infect
cell
treat
inhibitor
caus
shift
cypb
local
even
cytoplasm
distribut
fig
etohmock
row
larg
bleblik
structur
around
nucleu
fig
row
fig
left
anticypb
column
intens
yellow
costain
structur
antipdi
anticypb
antibodi
indic
coloc
two
protein
due
intens
concentr
refer
virusinduc
cypber
bleb
stain
antibodi
cell
organel
cisgolgi
autophagosom
pbodi
stress
granul
reveal
coloc
cypb
fig
viral
dsrna
coloc
neither
cypa
fig
row
cypber
bleb
fig
row
bleb
observ
infect
csaalvtreat
cell
inhibitor
prevent
viru
replic
western
blot
analysi
clearli
demonstr
downregul
cypb
cypa
presenc
inhibitor
independ
viru
infect
cell
fig
recent
studi
identifi
csa
broadspectrum
inhibitor
cov
replic
human
mous
cat
pig
bird
cyclophilin
presum
cellular
target
pfefferl
et
al
de
wild
et
al
extend
list
merscov
de
wild
et
al
arterivirus
equin
arter
viru
de
wild
et
al
indic
broad
activ
two
famili
coronavirida
arterivirida
order
nidoviral
shown
success
inhibit
replic
alv
posit
csa
deriv
carbajolozoya
et
al
requir
cypa
cypb
replic
demonstr
inhibit
compound
well
influenc
protein
interact
viru
inhibit
experi
fig
tabl
clearli
demonstr
highli
effect
inhibit
renilla
luciferaseexpress
decreas
ec
valu
h
pi
inhibit
pattern
alv
fig
compound
fig
csa
fig
similar
ec
valu
respect
log
titer
reduct
rang
h
time
point
cell
viabil
decreas
slightli
highest
drug
concentr
use
therapeut
index
valu
show
rather
high
level
tabl
gener
cov
inhibit
requir
low
micromolar
rang
csa
nonimmunosuppress
deriv
recent
found
us
carbajolozoya
et
al
pfefferl
et
al
other
de
wild
et
al
interestingli
inhibit
hcv
alv
commonli
observ
low
nanomolar
low
micromolar
concentr
respect
unravel
alv
effect
compound
current
explain
cyp
inhibitor
especi
alv
much
potent
prevent
hcv
oppos
cov
replic
inhibitori
activ
cov
rather
similar
one
explan
might
sever
cov
protein
depend
activ
cypa
andor
cypa
might
higher
affin
coronavir
compar
hcv
protein
thu
requir
higher
inhibitor
dose
abolish
interact
use
csh
rapamycin
control
compound
allow
transfer
nfat
nucleu
shown
csh
display
weak
bind
affin
cyclophilin
thu
cshcypa
complex
exist
bind
inactiv
calcineurin
rapamycin
target
fkbp
similarli
immunosuppress
earlier
report
describ
inhibit
fkbpbind
drug
carbajolozoya
et
al
howev
rapamycinfkbp
complex
inhibit
unrel
mtor
pathway
contrast
complex
bind
similar
csacyp
complex
thu
hamper
phosphatas
activ
consequ
nfat
pathway
drug
inhibit
replic
minor
reduct
observ
case
csh
might
attribut
weak
bind
affin
cyclophilin
trace
csa
csh
synthes
separ
quantit
enorm
experiment
expenditur
express
analysi
n
protein
support
inhibitori
effect
differ
substanc
n
requir
viru
replic
thu
essenti
viral
life
cycl
western
blot
analysi
fig
demonstr
lack
n
protein
express
infect
cell
alv
compound
csa
inhibitor
concentr
respect
fig
immunostain
cypa
mockand
cell
presenc
etoh
solvent
cyclophilin
inhibitor
csa
alisporivir
infect
moi
medium
remov
new
medium
ad
cell
contain
inhibitor
h
sampl
process
cypa
dsrna
stain
anticypa
green
abcam
antidsrna
red
scicon
respect
nuclei
visual
dapi
nucleocytoplasm
distribut
cypa
affect
presenc
viru
cyclophilin
inhibitor
dsrna
replic
marker
detect
presenc
csa
alv
exposur
time
respect
antibodi
differ
sampl
csh
rapamycin
attribut
reason
downregul
n
express
presenc
cyp
inhibitor
prevent
interact
n
cypa
split
yfp
proteinprotein
interact
experi
clearli
show
interact
two
protein
cell
abolish
presenc
inhibitor
fig
anoth
viral
protein
xdomain
also
interact
cypa
cyp
inhibitor
prevent
interact
suggest
differ
mechan
specul
differ
bind
site
chemic
bond
differ
time
point
interact
cypa
viral
protein
might
involv
viral
replic
csa
nonimmunosuppress
deriv
inhibit
replic
number
virus
includ
hcv
hbv
case
respons
cyclophilin
cypa
zhou
et
al
cypa
cypb
found
requir
fcov
replic
tanaka
et
al
recent
shown
cypa
express
essenti
cell
carbajolozoya
et
al
util
cypa
kd
knockdown
cell
line
origin
construct
studi
requir
stabl
cypa
hcv
replic
von
hahn
et
al
found
significantli
reduc
replic
luciferas
express
viru
von
brunn
et
al
indic
involv
cypa
also
replic
minor
replic
activ
might
explain
incomplet
suppress
cypa
shrnabas
knockdown
protein
one
abund
protein
total
cellular
protein
cell
cytoplasm
fischer
aumul
saphir
et
al
residu
molecul
cypa
might
suffici
exert
ppias
function
addit
cyp
ppias
might
overtak
cypa
function
case
cypa
kd
experi
interact
data
cypa
viral
protein
highli
like
cypa
play
import
role
replic
human
coronavirus
basi
sirnappia
ppib
knockdown
experi
recent
report
suggest
neither
cypa
cypb
requir
replic
sarscov
mous
hepat
viru
de
wild
et
al
howev
sirna
knockdown
residu
express
cypa
cypb
protein
might
left
enough
ppias
activ
level
infect
cell
support
viral
replic
role
cypb
cov
replic
clear
show
protein
level
subcellular
local
complet
chang
presenc
csa
alv
diverg
result
report
recent
studi
found
differ
replic
compar
ko
knockout
pool
cell
two
ko
clone
de
wild
et
al
merscov
titer
moder
diminish
wherea
equin
arter
viru
reduc
log
cell
line
gener
obvious
difficult
gener
clearcut
cypa
ko
hepatoma
cell
chromosom
transloc
carri
ppia
sequenc
observ
two
heterogen
clone
carri
eight
six
ppiaspecif
insertiondelet
indel
respect
could
isol
clone
identifi
cypaneg
western
blot
antibodi
direct
short
peptid
sequenc
cterminu
cypa
howev
region
locat
within
exon
exclud
frameshift
occur
upstream
antibodyrecogn
peptid
sequenc
within
exon
sequenc
interestingli
possibl
gener
ko
ko
ko
cell
clone
immunostain
cypb
mockand
cell
presenc
etoh
solvent
cyclophilin
inhibitor
csa
alisporivir
infect
moi
medium
remov
new
medium
ad
cell
contain
inhibitor
h
sampl
process
cypb
dsrna
stain
anticypb
green
antidsrna
red
scicon
respect
nuclei
visual
dapi
cypb
shift
even
cytoplasm
distribut
intens
bleblik
structur
presenc
viru
white
arrow
etoh
solvent
panel
csa
alv
led
reloc
cypb
granular
structur
nucleu
massiv
reduct
express
independ
viru
infect
dsrna
replic
marker
detect
presenc
csa
alv
exposur
time
respect
antibodi
differ
sampl
role
cypb
replic
seem
rather
peculiar
moment
protein
contain
er
retent
signal
promot
secret
medium
therefor
price
et
al
suggest
competit
csa
endogen
plasma
membran
protein
associ
cypb
favour
role
chaperon
protein
price
et
al
wb
find
strongli
decreas
cypb
cypa
express
level
reloc
sequestr
cypb
foci
nucleu
presenc
cyp
inhibitor
intriguingli
also
find
distinct
coloc
concentr
cypb
er
marker
protein
disulfideisomeras
pdi
virusinduc
cypber
bleb
upon
infect
occur
mockinfect
cell
indic
influenc
viral
compon
know
whether
reflect
accumul
secretori
block
anoth
mechan
protein
contain
chaperon
activ
highli
desir
identifi
possibl
effect
enzym
viral
protein
vice
versa
shown
earlier
sarscov
protein
bind
cyclophilin
bind
cypa
sarscov
n
protein
known
earli
educ
guess
find
use
surfac
plasmon
reson
biosensor
technolog
luo
et
al
support
spectrometr
profil
studi
show
incorpor
cypa
sarscov
virion
neuman
et
al
show
first
time
direct
interact
cypa
n
protein
x
adrp
protein
split
yfp
assay
fig
interestingli
cypa
n
cypa
x
interact
block
csa
nonimmunosuppress
deriv
alv
indic
import
cypa
correct
fold
ndure
replic
mechanist
suggest
cov
inhibit
direct
consequ
interrupt
interact
n
capsid
protein
cypa
cyclophilin
inhibitor
remain
determin
function
bind
cypa
whether
fig
coimmunostain
cypb
cell
organel
cell
identif
intens
cyclophilin
b
bleblik
structur
infect
cell
moi
h
pi
costain
anticypb
antibodi
direct
marker
er
antipdi
cisgolgi
autophagosom
antipbodi
stress
granul
antipabp
cyclophilin
b
normal
distribut
within
er
presenc
intriguingli
concentr
bleblik
structur
er
laboratori
result
clear
nonimmunosuppress
csa
deriv
block
cov
replic
furthermor
alv
alreadi
test
human
phase
ii
alv
well
new
csa
posit
compound
test
human
promis
broadlyact
candid
hta
anticoronavir
therapi
accord
result
cypa
repres
import
player
cov
replic
final
resolut
requir
differ
cyp
cov
replic
effort
put
construct
stabl
cyp
knockout
differ
covinfect
cell
line
involv
differ
viral
protein
none
